Main Menu

Professor Ian Judson

Team Leader

The alt text
Professor Ian Judson retired from the ICR in March 2016. His work focused on the development of new anticancer drugs that target sarcomas – cancers of the connective tissue. He has held positions in many research groups and is currently President of the British Sarcoma Group.
020 7808 2200 ORCID 0000-0002-4766-5304


Professor Judson trained at Cambridge University and King’s College Hospital Medical School. Having gained his MD at The Institute of Cancer Research, he trained in Medical Oncology at The Royal Marsden NHS Trust Foundation and was appointed Senior Lecturer in 1989.

His research initially focused on the development of new anticancer drugs, including both laboratory research and Phase I clinical trials. With the advent of molecularly targeted agents it became clear that pharmacodynamic biomarker studies, including functional imaging, were vital elements of the evaluation of new anticancer agents and many trials have since emphasised the need to validate such endpoints, including studies of angiogenesis and HSP90 inhibitors.

In addition to new drug development, Professor Judson has specialised in the management of sarcomas for the past 25 years and has made a particular study of gastrointestinal stromal tumours (GIST). He was a principal investigator in the Phase I/II trial of imatinib for GIST in 2000/1 and has been actively involved in research into the treatment of this disease since that time.

Many potential new targets for the treatment of sarcomas have been identified in recent years and The Royal Marsden has played an important role in a number of studies testing novel agents.

Professor Judson has been chief investigator for many national and international sarcoma trials and held the positions of Chairman of the National Cancer Research Institute (NCRI) Sarcoma Clinical Studies Group, Chairman of the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group, President of the Connective Tissue Oncology Society and President of the British Sarcoma Group. He was for many years Head of The Royal Marsden’s Sarcoma Unit and the Sarcoma Clinical Trials team at the ICR.

The Royal Marsden has one of the largest sarcoma units in Europe and an important programme of clinical and translational research in this field.